excelmigrationservices.com

Karuna Therapeutics KRTX Stock Price, News & Info The Motley Fool

price targets
solely for informational

One share of KRTX stock can currently be purchased for approximately $204.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Karuna Therapeutics does not have a long track record of dividend growth.

business

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies. According to analysts, Karuna Therapeutics’s stock has a predicted upside of 26.22% based on their 12-month price targets. Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. The company also focuses on developing other muscarinic-targeted drug candidates.

Real-time analyst ratings, insider transactions, earnings data, and more. Karuna Therapeutics’s market cap is calculated by multiplying KRTX’s current stock price of $198.44 by KRTX’s total outstanding shares of 34,473,905. The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.

The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Get MarketBeat All Access Free for 30 DaysJoin thousands of other investors who make better investing decisions with our premium tools. Access advanced stock screeners, portfolio monitoring tools, proprietary research reports, and more.

Analyst Ratings

Volatility profiles based on trailing-three-year calculations of the standard deviation of https://1investing.in/ investment returns. KRTX – Has potential to reach new highs giving up to 6RA move above 238$ could take this to new highs giving a R/R of more than 3.5R. If price goes above 262$ (78.6% Fib retracement), it’s likely it can go towards the 127.2% level around 300$. A move above 238$ could take this to new highs giving a R/R of more than 3.5R. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index quotes are real-time.

Karuna Therapeutics’ stock is owned by a number of institutional and retail investors. The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. MarketBeat has tracked 4 news articles for Karuna Therapeutics this week, compared to 4 articles on an average week.

  • We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
  • Overall, this stock passed 10/33 due dilligence checks and has average fundamentals, according to our automated analysis.
  • They issued an “overweight” rating and a $285.00 price target for the company.
  • Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
  • They issued a “neutral” rating and a $214.00 target price on the stock.

Cantor Fitzgerald started coverage on Karuna Therapeutics in a report on Tuesday, March 7th. They issued a “neutral” rating and a $214.00 target price on the stock. Finally, UBS Group assumed coverage on Karuna Therapeutics in a research report on Friday, January 27th. They set a “neutral” rating and a $209.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock.

About Karuna Therapeutics, Inc

The what is capital was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. Market cap is the total market value of a publicly traded company’s outstanding shares. Karuna Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. While Karuna Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys. Intraday Data provided by FACTSET and subject to terms of use.

15 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Karuna Therapeutics in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” KRTX shares.

Cambridge Investment Research Advisors Inc. now owns 2,172 shares of the company’s stock valued at $275,000 after buying an additional 105 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in Karuna Therapeutics by 53.7% during the 1st quarter. MetLife Investment Management LLC now owns 12,299 shares of the company’s stock worth $1,559,000 after buying an additional 4,297 shares during the last quarter. Finally, Rhumbline Advisers grew its position in shares of Karuna Therapeutics by 3.0% in the 1st quarter. Rhumbline Advisers now owns 23,080 shares of the company’s stock worth $2,926,000 after acquiring an additional 669 shares in the last quarter. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends.

hold ratings

Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its position in shares of Karuna Therapeutics by 19.6% in the 1st quarter. JPMorgan Chase & Co. now owns 20,218 shares of the company’s stock worth $2,563,000 after purchasing an additional 3,317 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Karuna Therapeutics by 132.7% in the first quarter. Bank of New York Mellon Corp now owns 211,678 shares of the company’s stock valued at $26,839,000 after buying an additional 120,709 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in Karuna Therapeutics by 5.1% during the first quarter.

Jefferies Keeps Their Buy Rating on Karuna Therapeutics (KRTX)

To see all exchange delays and terms of use please see Barchart’s disclaimer. 6.08% of the outstanding shares of Karuna Therapeutics have been sold short. Information is provided ‘as-is’ and solely for informational purposes and is not advice.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Please log in to your account or sign up in order to add this asset to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist.

month

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.

H.C. Wainwright maintains Karuna Therapeutics at Buy

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. CompareKRTX’s historical performanceagainst its industry peers and the overall market. Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion. By creating a free account, you agree to our terms of service.

WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Karuna Therapeutics stock was originally listed at a price of $20.02 in Jun 28, 2019.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

16.20% of the stock of Karuna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Only 3 people have added Karuna Therapeutics to their MarketBeat watchlist in the last 30 days. Only 8 people have searched for KRTX on MarketBeat in the last 30 days.

MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… KRTX longKRTX speculation If KRTX can hold the $98.00-$100.00 level and momentum continues this week there is room to $120 Pullback to $98 would make for an ideal entry. If the long setup fails, There is a good short opportunity under $95.80. KRTX speculation If KRTX can hold the $98.00-$100.00 level and momentum continues this week there is room to $120 Pullback to $98 would make for an ideal entry. Maintaining independence and editorial freedom is essential to our mission of empowering investor success.

Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters. According to analysts’ consensus price target of $276.87, Karuna Therapeutics has a forecasted upside of 35.0% from its current price of $205.11.

According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $276.87. Karuna Therapeutics Inc share price live 205.11, this page displays NASDAQ KRTX stock exchange data. View the KRTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Karuna Therapeutics Inc real time stock price chart below. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KRTX quote.

Leave A Comment